Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. demonstrates a positive financial outlook due to its strong technological capabilities, which are anticipated to enhance value-based care conversations and improve margin efficiencies through the integration of technology in recently acquired operations. The company benefits from robust core trends and an attractive earnings potential linked to its recent acquisitions, alongside significant market share in the pharmaceutical sector and a differentiated approach through advanced tech solutions. Furthermore, the effective use of robotic dispensing technology has increased operational efficiency, as evidenced by the rapid turnaround time for filling requisitions, typically under one day.

Bears say

Guardian Pharmacy Services Inc faces several critical challenges that contribute to a negative outlook on its stock. Key risks include potential changes in regulatory and reimbursement frameworks, which can adversely affect revenue streams and lower profitability. Additionally, the company may encounter operational hurdles such as difficulties in maintaining staffing levels, managing relationships with long-term care facilities, experiencing supply chain disruptions, and integrating acquisitions, all of which could impair its overall performance.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.